Share price · VTVT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VTVT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026-6.1%
Nothing announced by VTVT that day or the session before.
- 16 Nov 2026-10.2%
Nothing announced by VTVT that day or the session before.
- 1 Oct 2026+3.3%
Nothing announced by VTVT that day or the session before.
- 14 May 2026+21.4%
- Day beforevTv Therapeutics: Other material event
- 23 Apr 2026-13.8%
Nothing announced by VTVT that day or the session before.
- 16 Mar 2026+14.6%
- 10 Feb 2026+11.0%
Nothing announced by VTVT that day or the session before.
- 5 Feb 2026-14.8%
Nothing announced by VTVT that day or the session before.
- 20 Jan 2026-9.8%
Nothing announced by VTVT that day or the session before.
- 9 Jan 2026-13.4%
Nothing announced by VTVT that day or the session before.
Share of unusual movement by asset
For each asset, the share of VTVT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GlucokinaseSmall molecule | Type 1 Diabetes | |
| Phase 3 | PDE4Small molecule | Psoriasis | |
TTP273No recent activity | Phase 2 | GLP-1 receptorSmall molecule | Type 2 Diabetes |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $7.5M | $77M | $12M-$10M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $8.8M | $87M | $13M-$11M operating cash flow | report ↗ |
| 2026-Q1 | $37M | $9.0M | $98M | —$9.2M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $7.0M | $99M | $8.7M-$5.2M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $4.1M | $26M | $6.0M-$5.1M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $2.8M | $31M | $5.1M-$5.7M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $3.2M | $42M | $4.8M-$6.4M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $3.4M | $46M | $5.2M-$6.7M operating cash flow | report ↗ |
| 2024-Q1 | $1.0M | $2.6M | $52M | $4.9M-$7.3M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $2.8M | $8.2M | $6.7M-$4.8M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $4.7M | $13M | $5.6M-$6.2M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $3.9M | $19M | $4.5M-$5.2M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $3.1M | $15M | $4.3M-$8.8M operating cash flow | report ↗ |
| 2022-Q2 | <$0.1M | $2.2M | $18M | $3.1M$0.7M operating cash flow | report ↗ |
| 2022-Q1 | $2.0M | $3.1M | $12M | $7.0M-$1.0M operating cash flow | report ↗ |
| 2021-Q3 | $3.0M | $2.4M | $20M | $1.1M-$3.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $18M | $89M | $6.7M-$25M operating cash flow | report ↗ |
vTv Therapeutics reported FY2025 revenue of $0M, down 100% YoY, with R&D spend of $17.86M, up 54.6% YoY. Cash and equivalents were $88.93M at year-end, and the company reported a net loss of $26.97M with a quarterly net burn of $26.97M.
The company expects to complete enrollment in the CATT1 Phase 3 trial of cadisegliatin in the third quarter of 2026 and said its strengthened balance sheet provides funding runway well past the anticipated CATT1 topline readout. In February 2026, it received a $20.0M upfront payment under an amended licensing agreement with Newsoara granting worldwide rights to HPP737, and it also submitted a Phase 2 protocol for cadisegliatin in type 2 diabetes to the Abu Dhabi Department of Health and appointed new Scientific Advisory Board members.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-26 | Phillips Anne M. · director | Award / grant (derivative) | 6,000 | $35.08 | $210K | Form 4 |
| 2026-06-26 | Al-Marzooqi Fahed · director | Award / grant (derivative) | 6,000 | $35.08 | $210K | Form 4 |
| 2026-06-26 | AKKARAJU SRINIVAS · director | Award / grant (derivative) | 6,000 | $35.08 | $210K | Form 4 |
| 2026-06-26 | SPIEGELMAN DANIEL K · director | Award / grant (derivative) | 6,000 | $35.08 | $210K | Form 4 |
| 2026-06-26 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC · director; director; director; director; director; director | Award / grant (derivative) | 6,000 | — | — | Form 4 |
| 2026-06-26 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC · director; director; director; director; director; director | Award / grant (derivative) | 6,000 | — | — | Form 4 |
| 2026-02-17 | SEKHRI PAUL J · director, Pres, CEO and Exec Chairperson | Award / grant (derivative) | 140,000 | $36.92 | $5.2M | Form 4 |
| 2026-02-17 | Tung Michael Stephen · EVP & CFO | Award / grant (derivative) | 44,969 | $36.92 | $1.7M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 35 reporting institutions held 1.5M shares ($59.0M, 37.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SAMSARA BIOCAPITAL, LLC | 298,496 | $11.8M |
| 2 | FMR LLC | 260,391 | $10.3M |
| 3 | MILLENNIUM MANAGEMENT LLC | 206,288 | $8.2M |
| 4 | Siren, L.L.C. | 163,000 | $6.5M |
| 5 | BAKER BROS. ADVISORS LP | 148,314 | $5.9M |
| 6 | Trails Edge Capital Partners, LP | 139,578 | $5.5M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 108,922 | $4.3M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 32,886 | $1.3M |
| 9 | NORTHERN TRUST CORP | 18,052 | $716K |
| 10 | VANGUARD FIDUCIARY TRUST CO | 16,126 | $640K |
| 11 | 683 Capital Management, LLC | 16,000 | $635K |
| 12 | MARSHALL WACE, LLP | 13,389 | $531K |
| 13 | GOLDMAN SACHS GROUP INC | 13,350 | $529K |
| 14 | BlackRock, Inc. | 12,602 | $500K |
| 15 | STATE STREET CORP | 10,666 | $423K |